DEKA's News

January 16, 2018

MonaLisa Touch®: A new study has been stated in France

Evaluation Prospective de thérapeutiques Innovantes  des troubles de la sexualité après traitement du cancer du sein: un essai contrôlé randomisé. (Prospective Evaluation of Innovative Therapies of Sexual Troubles after Treatment for Breast Cancer : Randomized Control Trial).

This is the title of a multi-centre study on the MonaLisa Touch that is set to be launched in France in the coming months of 2018 under the auspices of the French Ministry of Health and National Institute of Cancer.

This important clinical study will last two years, involving about 500 cancer patients, 300 of whom will be involved in a randomised trial.

“The aim is to officially demonstrate the efficacy of the MonaLisa Touch treatment on vaginal atrophy in cancer patients and therefore enable all French cancer centres to use MonaLisa Touch therapy.” explains DEKA France General Manager Igor Pellissier.

Given the importance and significance of this study, 3 of the most prestigious centres in France were involved:

  • Henri Mondor Breast Center in Créteil - whose Director, Prof. Yazid Belkacemi, will coordinate the project

  • Hôpital Universitaire Carémeau (CHU) in Nîmes

  • Centre Régional de Lutte Contre le Cancer René Gauducheau (CRLCC) in Saint Herblain, near Nantes.

DEKA Export Director Mauro Galli explains: “This study opens up significant prospects, because it will be giving MonaLisa Touch definitive legitimacy, and at international level, not only in terms of its efficacy but also its total safety and lack of side effects, once again underlining the hugely revolutionary nature of this application”.

Information Support

Need more information about our products or events?






I have read and approved your Privacy Policy (View)
I agree to receive, from time to time, information on DEKA products, services and events.